acne
Conditions
Interventions
ALA-PDT:After the patient cleansed the face, the prepared 5% ALA was evenly applied to the subject's face with a thickness of about 1mm, protected from light for 0.5 hours, the residual ALA was wiped
ALA-PDT-ASA:After the patient cleansed the face, the prepared 5% ALA was evenly applied to the subject's face with a thickness of about 1mm, protected from light for 0.5 hours, the residual ALA was wi
Sponsors
Shanghai Skin Disease Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1) Age 18-55 years old, no cognitive dysfunction, male or female; 2) The diagnosis and grading of acne patients refer to the Pillsbury grading method, and the patients with grade II~IV moderate and severe acne located on the face are selected; 3) After giving a full explanation of the purpose and content of this clinical trial (including the matters to be complied with by the subjects, etc.), on the basis of full understanding, voluntarily sign the informed consent form to participate in the clinical trial.
Exclusion criteria
Exclusion criteria: 1) Those who are known to be allergic to the experimental drug or related drugs and products; 2) Those who have undergone photodynamic therapy within 12 weeks and those who have applied any other treatment that affects the study (3 months before enrollment, 1 month before enrollment, 1 month before enrollment, 2 weeks before enrollment, etc.); 3) Those who have taken phototoxic or photosensitizing drugs (such as sulfonamides, phenothiazines, etc.) within 8 weeks before enrollment; 4) Patients with other facial diseases that may affect the efficacy evaluation (dermatitis, eczema, other photodermatoses, etc.); 5) Those who are known to suffer from skin photoallergy, porphyria or allergy to ALA and photo; 6) Participation in any drug clinical trial (as a subject) within 1 month prior to participating in this trial 7) Combined with serious diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, etc.; 8) Those with scar constitution; 9) pregnant or lactating women, and subjects of childbearing potential (including males) who refuse to use adequate contraception during the study; 10) Subjects with severe physical or psychiatric illness that, in the opinion of the investigator, may affect treatment, evaluation, or poor compliance with the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of skin lesions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Skin barrier testing; | — |
Countries
China
Contacts
Public ContactWang Dixin
Skin Disease Hospital of Tongji University
Outcome results
None listed